Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage
Ann Rheum Dis
.
2021 Jul;80(7):823-824.
doi: 10.1136/annrheumdis-2021-220443.
Epub 2021 May 14.
Authors
Margot Van Mechelen
1
2
,
Rik Lories
3
2
Affiliations
1
Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium.
2
Rheumatology, University Hospitals Leuven, Leuven, Belgium.
3
Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium
[email protected]
.
PMID:
33990317
DOI:
10.1136/annrheumdis-2021-220443
No abstract available
Keywords:
ankylosing; arthritis; experimental; inflammation; spondylitis.
Publication types
Editorial
Comment
MeSH terms
Humans
Inflammation
Osteogenesis
Spondylarthritis* / drug therapy
Spondylitis, Ankylosing*
Tenascin
Substances
Tenascin